Q-omics provides the consensus-scored KCNJ14 profile across patient tissues and cancer cell-line models. KCNJ14 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KCNJ14 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, KCNJ14 RNA expression shows 17,957 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where KCNJ14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNJ14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNJ14 survival associations across molecular data types. KCNJ14 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNJ14 RNA expression–survival associations across cancer types. High KCNJ14 expression shows unfavorable associations in ACC, LUAD, COAD, KIRP and KIRC, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KCNJ14 RNA expression.
This table summarizes KCNJ14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for KCNJ14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNJ14 shows lower tumor expression in THCA and higher tumor expression in COAD, KIRC, STAD, KIRP and LIHC. The COAD box plot shows higher KCNJ14 RNA expression in tumor versus normal tissue (log2 FC = +1.157, t-test p < 0.001).
This table shows molecular features associated with KCNJ14 in patient tissues and cancer cell lines. In patient samples, KCNJ14 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNJ14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BONE.
